Recent News for EPZM - Epizyme, Inc.

Date Title
Apr 1 2 “Strong Buy” Stocks Insiders Are Snapping Up
Mar 30 Epizyme Comeback Is Likely, Price Makes It A Buy
Mar 26 The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs
Mar 25 Epizyme (EPZM) Down 22.9% Since Last Earnings Report: Can It Rebound?
Mar 15 Epizyme (EPZM) Presents At The Next EPIsode: Rewriting Oncology Treatment with Epigenetics - Slideshow
Mar 15 Epizyme (EPZM) Presents At Barclays Global Healthcare Conference - Slideshow
Mar 2 Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call
Feb 28 The Epizyme, Inc. (NASDAQ:EPZM) Analysts Have Been Trimming Their Sales Forecasts
Feb 25 Epizyme downgraded at Morgan Stanley citing pandemic impact
Feb 25 Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2021
Feb 24 Epizyme to Host Strategic Vision Call on March 2, 2021
Feb 24 Epizyme Inc (EPZM) Q4 2020 Earnings Call Transcript
Feb 23 Epizyme's (EPZM) CEO Rob Bazemore on Q4 2020 Results - Earnings Call Transcript
Feb 23 Return On Capital Employed Overview: Epizyme
Feb 23 Epizyme, Inc. 2020 Q4 - Results - Earnings Call Presentation
Feb 23 The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Feb 23 Epizyme: Q4 Earnings Insights
Feb 23 Epizyme Q4 top-line down 95%, Tazverik revenues reach $4.5M
Feb 23 Epizyme EPS misses by $0.06, beats on revenue
Feb 23 Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 23 Earnings Scheduled For February 23, 2021
Feb 22 Epizyme Q4 2020 Earnings Preview
Feb 20 The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings
Feb 16 Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences
Feb 14 Reassessing Epizyme
Back to the Main EPZM Page...